Daniel Smit
Dr. med. Dr. rer. biol. hum.
Daniel J. Smit
MD PhD
  • Arzt
  • Forschungsgruppenleiter
Arbeitsbereich

Standort

Campus Forschung N27 , 4. Etage, Raumnummer 04.023
Sprachen
Niederländisch (Muttersprache)
Deutsch
Englisch

Auszeichnungen

Publikationen

2024

Differential predictive value of tissue-specific PD-L1 expression scores in adjuvant immunotherapy of melanoma
Geidel G, Parnian N, Meß C, Schlepper N, Rünger A, Heidrich I, Hansen I, Smit D, Menz A, Pantel K, Schneider S, Kött J, Gebhardt C
J EUR ACAD DERMATOL. 2024;38(10):2017-2023.

K-Ras(V12) differentially affects the three Akt isoforms in lung and pancreatic carcinoma cells and upregulates E-cadherin and NCAM via Akt3
Geißert R, Lammert A, Wirth S, Hönig R, Lohfink D, Unger M, Pek D, Schlüter K, Scheftschik T, Smit D, Jücker M, Menke A, Giehl K
CELL COMMUN SIGNAL. 2024;22(1):85.

Liquid Biopsy – Ein neues diagnostisches Konzept in der Onkologie
Heidrich I, Roeper C, Rautmann C, Pantel K, Smit D
LARYNGO RHINO OTOL. 2024;103(1):40-46.

High Serum Levels of CCL20 Are Associated with Recurrence and Unfavorable Overall Survival in Advanced Melanoma Patients Receiving Immunotherapy
Kött J, Hoehne I, Heidrich I, Zimmermann N, Reese K, Zell T, Geidel G, Rünger A, Schneider S, Pantel K, Smit D, Gebhardt C
CANCERS. 2024;16(9):.

C-reactive protein flare predicts response to checkpoint inhibitor treatment in melanoma
Kött J, Zimmermann N, Zell T, Heidrich I, Geidel G, Rünger A, Smit D, Merkle M, Parnian N, Hansen I, Hoehne I, Abeck F, Torster L, Weichenthal M, Pantel K, Schneider S, Gebhardt C
J EUR ACAD DERMATOL. 2024;38(8):1575–1587.

Sentinel lymph node risk prognostication in primary cutaneous melanoma through tissue-based profiling, potentially redefining the need for sentinel lymph node biopsy
Kött J, Zimmermann N, Zell T, Rünger A, Heidrich I, Geidel G, Smit D, Hansen I, Abeck F, Schadendorf D, Eggermont A, Puig S, Hauschild A, Gebhardt C
EUR J CANCER. 2024;202:.

Multibiomarker panels in liquid biopsy for early detection of pancreatic cancer - a comprehensive review
Reese K, Pantel K, Smit D
J EXP CLIN CANC RES. 2024;43(1):.

Functional characterization of PI3K C2 domain mutations detected in breast cancer circulating tumor cells and metastatic cells
Smit D, Brauer H, Horn S, Yigit G, Haider M, Pogenberg V, Schumacher U, Pantel K, Jücker M
CELL SIGNAL. 2024;121:.

Analysis of the Plasticity of Circulating Tumor Cells Reveals Differentially Regulated Kinases During the Suspension-to-Adherent Transition
Smit D, Hoffer K, Bettin B, Kriegs M, Cayrefourcq L, Schumacher U, Pantel K, Alix-Panabières C, Jücker M
CANCER MED-US. 2024;13(20):e70339.

Circulating tumor cells as liquid biopsy markers in cancer patients
Smit D, Pantel K
MOL ASPECTS MED. 2024;96:101258.

Clinical applications of circulating tumor cells in patients with solid tumors
Smit D, Schneegans-Murano S, Pantel K
CLIN EXP METASTAS. 2024;41(4):403-411.

All Three AKT Isoforms Can Upregulate Oxygen Metabolism and Lactate Production in Human Hepatocellular Carcinoma Cell Lines
Tian L, Smit D, Popova N, Horn S, Velasquez L, Huber S, Jucker M
INT J MOL SCI. 2024;25(4):.

2023

Liquid Biopsy  – Ein neues diagnostisches Konzept in der Onkologie
Heidrich I, Roeper C, Rautmann C, Pantel K, Smit D
DEUT MED WOCHENSCHR. 2023;148(10):597-604.

Impact of AKT1 on cell invasion and radiosensitivity in a triple negative breast cancer cell line developing brain metastasis
Kempska J, Oliveira-Ferrer L, Grottke A, Qi M, Alawi M, Meyer F, Borgmann K, Hamester F, Eylmann K, Rossberg M, Smit D, Jücker M, Laakmann E, Witzel I, Schmalfeldt B, Müller V, Legler K
FRONT ONCOL. 2023;13:1129682.

„Liquid biopsy“ – schon reif für Therapieentscheidungen?
Roeper C, Hoehne I, Schlepper N, Koch C, Pantel K, Smit D
best practice onkologie. 2023;18(5):194 - 202.

The Role of PI3K/AKT/mTOR Signaling in Hepatocellular Carcinoma Metabolism
Tian L, Smit D, Jücker M
INT J MOL SCI. 2023;24(3):.

2022

TIGIT blockade repolarizes AML-associated TIGIT+ M2 macrophages to an M1 phenotype and increases CD47-mediated phagocytosis
Brauneck F, Fischer B, Witt M, Muschhammer J, Oelrich J, da Costa Avelar P, Tsoka S, Bullinger L, Seubert E, Smit D, Bokemeyer C, Ackermann C, Wellbrock J, Haag F, Fiedler W
J IMMUNOTHER CANCER. 2022;10(12):.

The role of sphingosine-1-phosphate in bone remodeling and osteoporosis
Grewe J, Knapstein P, Donat A, Jiang S, Smit D, Xie W, Keller J
BONE RES. 2022;10(1):.

MicroRNAs: Emerging Regulators of Metastatic Bone Disease in Breast Cancer
Haider M, Smit D, Taipaleenmäki H
CANCERS. 2022;14(3):.

Combined Targeting of AKT and mTOR Inhibits Tumor Formation of EpCAM+ and CD90+ Human Hepatocellular Carcinoma Cells in an Orthotopic Mouse Model
Moustafa M, Dähling K, Günther A, Riebandt L, Smit D, Riecken K, Schröder C, Zhuang R, Krech T, Kriegs M, Fehse B, Izbicki J, Fischer L, Nashan B, Li J, Jücker M
CANCERS. 2022;14(8):.

AKT Isoforms as a Target in Cancer and Immunotherapy
Smit D, Jücker M
2022. PI3K and AKT Isoforms in Immunity. Dominguez-Villar M (Hrsg.). 1. Aufl. Cham: Springer, 409-436.

2021

Interleukins as Mediators of the Tumor Cell-Bone Cell Crosstalk during the Initiation of Breast Cancer Bone Metastasis
Haider M, Ridlmaier N, Smit D, Taipaleenmäki H
INT J MOL SCI. 2021;22(6):2898.

Role of miRNAs in Breast Cancer-induced Bone Disease
Haider M, Zarrer J, Smit D, Hesse E, Taipaleenmäki H
OSTEOLOGIE. 2021;30(3):211-221.

Knockdown of AKT3 Activates HER2 and DDR Kinases in Bone-Seeking Breast Cancer Cells, Promotes Metastasis In Vivo and Attenuates the TGFβ/CTGF Axis
Hinz N, Baranowsky A, Horn M, Kriegs M, Sibbertsen F, Smit D, Clezardin P, Lange T, Schinke T, Jücker M
CELLS-BASEL. 2021;10(2):.

Combined Targeting of AKT and mTOR Synergistically Inhibits Formation of Primary Colorectal Carcinoma Tumouroids In Vitro: A 3D Tumour Model for Pre-therapeutic Drug Screening
Nörz D, Mullins C, Smit D, Linnebacher M, Hagel G, Mirdogan A, Siekiera J, Ehm P, Izbicki J, Block A, Thastrup O, Jücker M
ANTICANCER RES. 2021;41(5):2257-2275.

High Serum Levels of Wnt Signaling Antagonist Dickkopf-Related Protein 1 Are Associated with Impaired Overall Survival and Recurrence in Esophageal Cancer Patients
Ramirez J, Smit D, Viol F, Schrader J, Ghadban T, Pantel K, Izbicki J, Reeh M
CANCERS. 2021;13(19):.

Circulating tumor cells as a promising target for individualized drug susceptibility tests in cancer therapy
Smit D, Pantel K, Jücker M
BIOCHEM PHARMACOL. 2021;188:114589.

2020

The Endosteal Niche in Breast Cancer Bone Metastasis
Haider M, Smit D, Taipaleenmäki H
FRONT ONCOL. 2020;10:335.

Characterization of circulating breast cancer cells with tumorigenic and metastatic capacity
Koch C, Kuske A, Joosse S, Yigit G, Sflomos G, Thaler S, Smit D, Werner S, Borgmann K, Gärtner S, Mossahebi Mohammadi P, Battista L, Cayrefourcq L, Altmüller J, Salinas-Riester G, Raithatha K, Zibat A, Goy Y, Ott L, Bartkowiak K, Tan T, Zhou Q, Speicher M, Müller V, Gorges T, Jücker M, Thiery J, Brisken C, Riethdorf S, Alix-Panabières C, Pantel K
EMBO MOL MED. 2020;12(9):.

Combined Targeting of AKT and mTOR Inhibits Proliferation of Human NF1-Associated Malignant Peripheral Nerve Sheath Tumour Cells In Vitro but not in a Xenograft Mouse Model In Vivo
Schulte A, Ewald F, Spyra M, Smit D, Jiang W, Salamon J, Jücker M, Mautner V
INT J MOL SCI. 2020;21(4):.

High Sensitivity of Circulating Tumor Cells Derived from a Colorectal Cancer Patient for Dual Inhibition with AKT and mTOR Inhibitors
Smit D, Cayrefourcq L, Haider M, Hinz N, Pantel K, Alix-Panabières C, Jücker M
CELLS-BASEL. 2020;9(9):.

Differential regulation of extracellular matrix proteins in three recurrent liver metastases of a single patient with colorectal cancer
Voß H, Wurlitzer M, Smit D, Ewald F, Alawi M, Spohn M, Indenbirken D, Omidi M, David K, Juhl H, Simon R, Sauter G, Fischer L, Izbicki J, Molloy M, Nashan B, Schlüter H, Jücker M
CLIN EXP METASTAS. 2020;37(6):649-656.

Pathological Crosstalk between Metastatic Breast Cancer Cells and the Bone Microenvironment
Zarrer J, Haider M, Smit D, Taipaleenmäki H
BIOMOLECULES. 2020;10(2):.

Letzte Aktualisierung aus dem FIS: 13.12.2024 - 23:33 Uhr